

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBLT-CELL CROSSMATCHING RESULTS OF SAMPLE 2A03/2014

DESPATCHED ON 25TH MARCH 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A24, A34; B44, B64; Cw4, Cw8; DR4, DR7; DQ2, DQ8

Summary of Results					Summary of Results				
Total tested	46	47	47	47	32	34	33	33	
Positive	0	47	2	0	0	34	2	1	
Negative	46	0	45	47	32	0	31	32	
Not Tested	5	5	5	5	0	0	0	0	
% Positive	0.0%	100.0%	4.3%	0.0%	0.0%	100.0%	6.1%	3.0%	
% Negative	100.0%	0.0%	95.7%	100.0%	100.0%	0.0%	93.9%	97.0%	
Consensus	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
HLA Antibody (Defined By CDC)	DR3	B14+	DR3	A2, B17					
Without DTT					With DTT (Not assessed)				
Lab No.	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
112	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
114	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
116	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
117	Negative	Positive	Negative	Negative					
119	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
120	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	
126	Negative	Positive	Negative	Negative					
128	Negative	Positive	Negative	Negative		Positive			
136	Negative	Positive	Negative	Negative					
139	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
143	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
145	Negative	Positive	Negative	Negative					
147	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
149	Negative	Positive	Negative	Negative					
154	Negative	Positive	Negative	Negative					
159	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
162	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
164	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
169	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
174	Uninterpretable	Positive	Negative	Negative	Uninterpretable	Positive	Negative	Negative	10-15% dead cells found in the negative and diluent controls hindered the interpretation, particularly for serum 1
181	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
186	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
189	NT	NT	NT	NT					Not tested due to low cell count
190	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
193	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
194	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
195	NT	NT	NT	NT					
197	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
202	NT	NT	NT	NT					
204	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
206	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
209	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
210	NT	NT	NT	NT					
216	Negative	Positive	Negative	Negative					
223	Negative	Positive	Negative	Negative					
227	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
229	NT	NT	NT	NT					Not tested due to low cell viability
232	Negative	Positive	Negative	Negative					
235	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
238	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
243	Negative	Positive	Negative	Negative					
245	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
252	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
259	Negative	Positive	Negative	Negative					
260	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
262	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
268	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
271	Negative	Positive	Negative	Negative					
284	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
293	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
294	Negative	Positive	Negative	Negative					
297	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	

PLEASE NOTE: NEXT DISTRIBUTION IS ON 03RD JUNE 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A03/2014

DESPATCHED ON 25TH MARCH 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used PBL	T-cells	Immunobeaded cells used?	Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						PBL	T-cells		pre C'	post C'	
112	1	4	1	1	1	6	1	1	27-Mar	28-Mar	Yes		No	90		One Lambda	30	60	Stain Fix
114	1	8	1	1	1	8	1	1	27-Mar	27-Mar		Yes	Yes			One Lambda	30	60	EB/AO
116	1	8	4	1	1	8	8	1	26-Mar	27-Mar		Yes	No	90		Cedarlane	20	60	EB/AO
117	1	8	1	1					27-Mar	28-Mar	Yes		No	60		Pel-Freeze	80	120	Eosin
119	1	8	1	1	1	8	1	1	26-Mar	26-Mar	Yes		No	95		Biorad	30	60	Eosin
120	1	8	1	1	1	8	1	1	27-Mar	27-Mar		Yes	Yes	100		Servibio	30	60	EB/AO
126		100%							26-Mar	26-Mar		Yes	Yes	100		Cedarlane	30	40	EB/AO
128	1	8	1	1		8			26-Mar	28-Mar	Yes		No	90		One Lambda	45	90	
136	1	8	1	1					26-Mar	27-Mar			Yes	93		In-house	60	60	
139	1	8	1	1	1	8	1	1	31-Mar	31-Mar	Yes	Yes	Yes	90	90	Cedarlane	30	60	Eosin
143	1	8	1	1	1	8	1	1	27-Mar	28-Mar		Yes	Yes	95		Cedarlane	30	60	Eosin
145		8							26-Mar	27-Mar		Yes	Yes	100		Invitrogen	45	45	EB/AO
147	1	8	1	1	1	8	1	1	26-Mar	26-Mar		Yes	Yes	100		In-house	30	60	Fluoroquen
149		6-8							27-Mar	28-Mar	Yes			87			60	60	Eosin
154	1	8	1	1					25-Mar	27-Mar		Yes	No	90		Cedarlane	30	60	Eosin
159	1	8	1	1	1	8	1	1	27-Mar	27-Mar		Yes	Yes	95		In-house	30	60	Fluoroquen
162		8				8			26-Mar	27-Mar		Yes	Yes	100		Cedarlane	60	60	
164									26-Mar	27-Mar		Yes	Yes	80		Servibio	45	90	EB/AO
169	1	6	1	1	1	6	1	1	27-Mar	28-Mar		Yes	No	60		One Lambda	35	75	Fluoroquen
174		90-100%				90-100%			31-Mar	31-Mar	Yes			99		One Lambda	60	120	Eosin
181		8				8			26-Mar	27-Mar	Yes		No	100		Cedarlane	30	45	EB
186	0	8	0	0	0	8	0	0	27-Mar	27-Mar		Yes	Yes	99		Invitrogen	30	60	EB
189	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
190	1%	99%	1%	1%	1%	100%	1%	1%	26-Mar	27-Mar		Yes	Yes	99	99	Cedarlane	30	60	Fluoroquen
193	1	8	1	1	1	8	1	1	26-Mar	26-Mar	Yes	Yes	No	99	99	Cedarlane	30	60	Fluoroquen
194	1	8	1	1	1	8	1	1	26-Mar	26-Mar		Yes	Yes	98			30	45	Fluoroquen
195	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
197		Strong				Strong			27-Mar	28-Mar		Yes	Yes	90	90	One Lambda	30	60	Fluoroquen
202																			
204	1	8	1	1	1	8	1	1	26-Mar	26-Mar		Yes	No	95		Cedarlane	45	90	Fluoroquen
206	1	8	1	1	1	8	1	1	26-Mar	27-Mar		Yes	Yes	100		Cedarlane	30	45	Fluoroquen
209		8				6			27-Mar	27-Mar	Yes		No	95		Ingen	30	60	Fluoroquen
210																			
216	1	8	1	1					27-Mar	27-Mar	Yes		No	95		Biorad	30	60	PI
223	1	8	1	1					27-Mar	28-Mar		Yes	Yes	100		Biorad	45	60	EB/AO
227		8				8			26-Mar	26-Mar		Yes	Yes	90		Immucor	30	60	Fluoroquen
229	NT	NT	NT	NT	NT	NT	NT	NT	02-Apr	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
232	0%	100%	0%	0%					01-Apr	02-Apr		Yes	Yes	95		Biorad	45	60	EB/AO
235	1	8	8	1	1	8	6	1	26-Mar	26-Mar	Yes		No	90		Biorad	30	60	Eosin
238	1	8	1	1	1	8	1	1	26-Mar	27-Mar	Yes		Yes	95	95	Invitrogen	45	90	Fluoroquen
243	1	8	2	2					26-Mar	27-Mar	Yes		Yes	90	80	Biorad	30	60	Fluoroquen
245	1	8	1	1	1	8	1	1	26-Mar	26-Mar	Yes	Yes	No	100	100	BAG	45	60	EB/AO
252	2	4-6	2	2	2	4-6	2	2	27-Mar	27-Mar		Yes	Yes	40		Biorad	30	60	
259									27-Mar	27-Mar	Yes	Yes	Yes	85	90	Biorad	30	60	AO/PI
260		++++				++++			27-Mar	27-Mar		Yes	Yes	85		Biorad	30	60	EB/AO
262		8				8			26-Mar	26-Mar	Yes	Yes	Yes	85	85	Invitrogen	30	60	Eosin
268	1	8	1	1	1	8	1	1	26-Mar	27-Mar		Yes	No	85		Gentrak	30	60	EB/AO
271	1	8	1	1					27-Mar	27-Mar		Yes	Yes	95		One Lambda	30	60	EB/AO
284	1	8	1	1	1	8	1	1	26-Mar	27-Mar		Yes	Yes	99		Cedarlane	40	60	EB/AO
293		8				8			27-Mar	27-Mar		Yes	Yes	70		Invitrogen	60	120	Eosin
294	0	8	0	0					26-Mar	26-Mar		Yes	Yes	100		Life Technologies	30	30	Fluoroquen
297	1	8	1	1	1	8	1	1	26-Mar	27-Mar	Yes	Yes	Yes	70	70	Cedarlane	30	60	EB/AO

AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A03/2014

DESPATCHED ON 25TH MARCH 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A24, A34; B44, B64; Cw4, Cw8; DR4, DR7; DQ2, DQ8

Summary of Results					Summary of Results				
Total tested	34	35	34	32	28	28	27	27	
Positive	1	35	3	3	1	28	0	1	
Negative	33	0	31	29	27	0	27	26	
Not Tested	2	2	3	4	0	0	1	1	
% Positive	2.9%	100.0%	8.8%	9.4%	3.6%	100.0%	0.0%	3.7%	
% Negative	97.1%	0.0%	91.2%	90.6%	96.4%	0.0%	100.0%	96.3%	
Consensus	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
HLA Antibody (Defined By CDC)	DR3	B14+	DR3	A2, B17					
Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
114	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
120	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
126	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	
139	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
145	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
147	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
154	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
159	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
162	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
164	Negative	Positive	Positive	Negative	Negative	Positive	Negative	Negative	
169	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
181	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
186	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
190	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
193	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
194	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
195	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
197	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
204	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
206	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
209	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
210	NT	NT	NT	NT					
223	NT	NT	NT	NT					Not tested due to low viability
227	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
238	Negative	Positive	NT	NT	Negative	Positive	NT	NT	Not enough cells in the well to read
243	Equivocal	Positive	Negative	Equivocal					Serum 1 and 4 - Low cell count. The cells die with only complement addition. Poor cell yield.
245	Positive	Positive	Negative	Weak Positive	Positive	Positive	Negative	Negative	
252	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
259	Negative	Positive	Positive	Negative	Negative	Positive	Negative	Negative	
260	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
262	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
268	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
271	Negative	Positive	Negative	NT					Unable to interpret B-cell CDC crossmatch
284	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
293	Negative	Positive	Positive	Negative	Negative	Positive	Negative	Negative	
294	Negative	Positive	Negative	Negative					
297	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	

PLEASE NOTE: NEXT DISTRIBUTION IS ON 03RD JUNE 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A03/2014

DESPATCHED ON 25TH MARCH 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
114	1	8	1	1	1	8	1	1	27-Mar	27-Mar	Yes		One Lambda	30	60	EB/AO
120	1	8	1	1	1	8	1	1	27-Mar	27-Mar	Yes	100	Servibio	30	60	EB/AO
126				15%					26-Mar	26-Mar	Yes	100	Cedarlane	30	40	EB/AO
139	1	8	1	1	1	8	1	1	31-Mar	31-Mar	Yes	90	Cedarlane	30	60	Eosin
145		8							26-Mar	27-Mar	Yes	100	Invitrogen	45	45	EB/AO
147	1	8	1	1	1	8	1	1	26-Mar	26-Mar	Yes	100	In-house	30	60	Fluoroquen
154	1	8	1	1					25-Mar	27-Mar	No	90	Cedarlane	30	60	Eosin
159	1	8	1	1	1	8	1	1	27-Mar	27-Mar	Yes	90	In-house	30	60	Fluoroquen
162		8							26-Mar	27-Mar	Yes	100	Cedarlane	60	60	
164									26-Mar	27-Mar	Yes	70	Servibio	45	90	EB/AO
169	1	8	1	1	1	6	1	1	27-Mar	28-Mar	Yes	60	One Lambda	35	75	Fluoroquen
181		8							26-Mar	27-Mar	Yes	100	Cedarlane	30	45	EB
186	0	8	0	0	0	8	0	0	27-Mar	27-Mar	Yes	99	Invitrogen	30	60	EB
190	1%	99%	1%	1%	1%	100%	1%	1%	26-Mar	27-Mar	Yes	98	Cedarlane	30	60	Fluoroquen
193	1	8	1	1	1	8	1	1	26-Mar	26-Mar	Yes	99	Cedarlane	30	60	Fluoroquen
181		8							26-Mar	27-Mar	Yes	100	Cedarlane	30	45	EB
194	1	8	1	1	1	8	1	1	26-Mar	26-Mar	Yes	95	In-house	30	45	Fluoroquen
195	2	8	2	8	2	8	2	6	28-Mar	28-Mar	Yes	70	Invitrogen	60	90	Fluoroquen
197		Strong				Strong			27-Mar	28-Mar	Yes	80	One Lambda	30	60	Fluoroquen
204	1	8	1	1	1	8	1	1	26-Mar	26-Mar	Yes	85	Cedarlane	45	90	Fluoroquen
206	1	8	1	1	1	8	1	1	26-Mar	27-Mar	Yes	100	Cedarlane	30	45	Fluoroquen
209		8							27-Mar	27-Mar	Yes	95	Ingen	30	60	Fluoroquen
210																
223	NT	NT	NT	NT	NT	NT	NT	NT	27-Mar	28-Mar	Yes	60	Biorad	45	60	EB/AO
227		8							26-Mar	26-Mar	Yes	90	Immucor	30	60	Fluoroquen
238	1	8	NT	NT	1	8	NT	NT	26-Mar	27-Mar	Yes	85	Invitrogen	45	90	Fluoroquen
243		8	2						26-Mar	27-Mar	Yes	30	Biorad	30	60	Fluoroquen
245	8	8	1	2	8	8	1	1	26-Mar	26-Mar	Yes	100	BAG	45	45	EB/AO
252	2	4-6	2	2	2	4-6	2	2	27-Mar	27-Mar	Yes	20	Biorad	30	60	
259									27-Mar	27-Mar	Yes	85	Biorad	30	60	AO/PI
260		++++				++++			27-Mar	27-Mar	Yes	60	Biorad	30	60	EB/AO
262		8							26-Mar	26-Mar	Yes	50	Invitrogen	60	90	Eosin
268	1	8	1	1	1	8	1	1	26-Mar	27-Mar	Yes	85	Gentrak	30	60	EB/AO
271	1	8	1	NT					27-Mar	27-Mar	Yes	45	One Lambda	30	60	EB/AO
284	1	8	1	1	1	8	1	1	26-Mar	27-Mar	Yes	98	Cedarlane	40	60	EB/AO
293		8	4						27-Mar	27-Mar	Yes	50	Invitrogen	60	120	Eosin
294	0	8	0	0					26-Mar	26-Mar	Yes	100	Life Technologies	30	30	Fluoroquen
297	1	8	1	1	1	8	1	1	26-Mar	27-Mar	Yes	70	Cedarlane	30	60	EB/AO